{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:41:57Z","timestamp":1781196117083,"version":"3.54.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Steven Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), grouped together under the terminology of epidermal necrolysis (EN), are a spectrum of life-threatening dermatologic conditions. A lack of standardization and validation for existing endpoints has been identified as a key barrier to the comparison of these therapies and development of evidenced-based treatment. Following PRISMA guidelines, we conducted a systematic review of prospective studies involving systemic or topical treatments for EN, including dressing and ocular treatments. Outcomes were separated into mortality assessment, cutaneous outcomes, non-cutaneous clinical outcomes, and mucosal outcomes. The COSMIN Risk of Bias tool was used to assess the quality of studies on reliability and measurement error of outcome measurement instruments. Outcomes across studies assessing treatment in the acute phase of EN were varied. Most data came from prospective case reports and cohort studies representing the lack of available randomized clinical trial data available in EN. Our search did not reveal any EN-specific validated measures or scoring tools used to assess disease progression and outcomes. Less than half of included studies were considered \u201cadequate\u201d for COSMIN risk of bias in reliability and measurement error of outcome measurement instruments. With little consensus about management and treatment of EN, consistency and validation of measured outcomes is of the upmost importance for future studies to compare outcomes across treatments and identify the most effective means of combating the disease with the highest mortality managed by dermatologists.<\/jats:p>","DOI":"10.1007\/s00403-024-03062-5","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T09:01:42Z","timestamp":1718442102000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Outcome measurements in epidermal necrolysis: a systematic review"],"prefix":"10.1007","volume":"316","author":[{"given":"Karissa","family":"Libson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Kirven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham M.","family":"Korman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin H.","family":"Kaffenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,15]]},"reference":[{"key":"3062_CR1","doi-asserted-by":"publisher","unstructured":"Dobry AS, Himed S, Waters M, Kaffenberger BH (2022) Scoring assessments in Stevens-Johnson syndrome and toxic epidermal necrolysis. Front Med (Lausanne) 9. https:\/\/doi.org\/10.3389\/fmed.2022.883121","DOI":"10.3389\/fmed.2022.883121"},{"key":"3062_CR2","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366. https:\/\/doi.org\/10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"issue":"8","key":"3062_CR3","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/1346-8138.12925","volume":"42","author":"M Aihara","year":"2015","unstructured":"Aihara M, Kano Y, Fujita H et al (2015) Efficacy of additional i.v. immunoglobulin to steroid therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis. J Dermatol 42(8):768\u2013777. https:\/\/doi.org\/10.1111\/1346-8138.12925","journal-title":"J Dermatol"},{"issue":"3","key":"3062_CR4","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1172\/JCI93349","volume":"128","author":"CW Wang","year":"2018","unstructured":"Wang CW, Yang LY, Chen CB, Ho HC, Hung SI, Yang CH, Chang CJ, Su SC, Hui RC, Chin SW, Huang LF, Lin YY, Chang WY, Fan WL, Yang CY, Ho JC, Chang YC, Lu CW, Chung WH (2018) The Taiwan severe cutaneous adverse reaction (TSCAR) Consortium. Randomized, controlled trial of TNF-\u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest 128(3):985\u2013996. https:\/\/doi.org\/10.1172\/JCI93349","journal-title":"J Clin Invest"},{"issue":"9140","key":"3062_CR5","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","volume":"352","author":"P Wolkenstein","year":"1998","unstructured":"Wolkenstein P, Latarjet J, Roujeau JC et al (1998) Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 352(9140):1586\u20131589. https:\/\/doi.org\/10.1016\/S0140-6736(98)02197-7","journal-title":"Lancet"},{"issue":"6","key":"3062_CR6","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s00403-005-0607-3","volume":"297","author":"P Paquet","year":"2005","unstructured":"Paquet P, Jacob E, Damas P, Pirson J, Pi\u00e9rard G (2005) Analytical quantification of the inflammatory cell infiltrate and CD95R expression during treatment of drug-induced toxic epidermal necrolysis. Arch Dermatol Res 297(6):266\u2013273. https:\/\/doi.org\/10.1007\/s00403-005-0607-3","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"3062_CR7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.0906-6705.2006.00426.x","volume":"15","author":"P Paquet","year":"2006","unstructured":"Paquet P, Kaveri S, Jacob E, Pirson J, Quatresooz P, Pi\u00e9rard GE (2006) Skin immunoglobulin deposition following intravenous immunoglobulin therapy in toxic epidermal necrolysis. Exp Dermatol 15(5):381\u2013386. https:\/\/doi.org\/10.1111\/j.0906-6705.2006.00426.x","journal-title":"Exp Dermatol"},{"issue":"5","key":"3062_CR8","doi-asserted-by":"publisher","first-page":"686","DOI":"10.4103\/0378-6323.116738","volume":"79","author":"GK Singh","year":"2013","unstructured":"Singh GK, Chatterjee M, Verma R (2013) Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid. Indian J Dermatol Venereol Leprol 79(5):686\u2013692. https:\/\/doi.org\/10.4103\/0378-6323.116738","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"1","key":"3062_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/ARCHDERM.139.1.33","volume":"139","author":"N Bachot","year":"2003","unstructured":"Bachot N, Revuz J, Roujeau JC (2003) Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 139(1):33\u201336. https:\/\/doi.org\/10.1001\/ARCHDERM.139.1.33","journal-title":"Arch Dermatol"},{"issue":"4","key":"3062_CR10","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/J.1365-2133.2010.09863.X","volume":"163","author":"L Valeyrie-Allanore","year":"2010","unstructured":"Valeyrie-Allanore L, Wolkenstein P, Brochard L et al (2010) Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 163(4):847\u2013853. https:\/\/doi.org\/10.1111\/J.1365-2133.2010.09863.X","journal-title":"Br J Dermatol"},{"issue":"2","key":"3062_CR11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/S004310050561","volume":"156","author":"T Kakourou","year":"1997","unstructured":"Kakourou T, Klontza D, Soteropoulou F, Kattamis C (1997) Corticosteroid treatment of Erythema Multiforme major (Stevens-Johnson syndrome) in children. Eur J Pediatr 156(2):90\u201393. https:\/\/doi.org\/10.1007\/S004310050561","journal-title":"Eur J Pediatr"},{"key":"3062_CR12","doi-asserted-by":"crossref","unstructured":"Viard I, Wehrli P, Bullani R et al (1998) Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. 282","DOI":"10.1126\/science.282.5388.490"},{"issue":"3","key":"3062_CR13","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/J.OPHTHA.2015.10.027","volume":"123","author":"N Sharma","year":"2016","unstructured":"Sharma N, Thenarasun SA, Kaur M et al (2016) Adjuvant role of Amniotic Membrane Transplantation in Acute Ocular Stevens-Johnson syndrome: a Randomized Control Trial. Ophthalmology 123(3):484\u2013491. https:\/\/doi.org\/10.1016\/J.OPHTHA.2015.10.027","journal-title":"Ophthalmology"},{"key":"3062_CR14","doi-asserted-by":"publisher","unstructured":"Tripathi A, Ditto AM, Grammer LC et al (2000) Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome: a total series of 67 cases. Allergy Asthma Proc. ;21(2):101\u2013105. https:\/\/doi.org\/10.2500\/108854100778250914","DOI":"10.2500\/108854100778250914"},{"key":"3062_CR15","doi-asserted-by":"publisher","unstructured":"Cheriyan S, Patterson R, Greenberger PA, Grammer LC, Latall J (1995) The outcome of Stevens-Johnson syndrome treated with corticosteroids. Allergy Proc. ;16(4):151\u2013155. https:\/\/doi.org\/10.2500\/108854195778666793","DOI":"10.2500\/108854195778666793"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03062-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03062-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03062-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T20:32:35Z","timestamp":1725913955000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03062-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,15]]},"references-count":15,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["3062"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03062-5","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,15]]},"assertion":[{"value":"22 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required, as this is a secondary analysis of existing deidentified data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"IRB approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"Dr. Benjamin Kaffenberger is an investigator for BMS, Biogen, Merck, InflaRx, OnQuality Pharmaceuticals, and the Dermatology Foundation and has consulted for Biogen, Onquality, Novocure, Novartis, and Elsevier.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Dr. Benjamin Kaffenberger is an investigator for BMS, Biogen, Merck, InflaRx, OnQuality Pharmaceuticals, and the Dermatology Foundation and has consulted for Biogen, Onquality, Novocure, Novartis, and Elsevier.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"392"}}